HK1036997A1 - Peptides - Google Patents

Peptides

Info

Publication number
HK1036997A1
HK1036997A1 HK01107827A HK01107827A HK1036997A1 HK 1036997 A1 HK1036997 A1 HK 1036997A1 HK 01107827 A HK01107827 A HK 01107827A HK 01107827 A HK01107827 A HK 01107827A HK 1036997 A1 HK1036997 A1 HK 1036997A1
Authority
HK
Hong Kong
Prior art keywords
peptides
Prior art date
Application number
HK01107827A
Other languages
English (en)
Inventor
Gustav Gaudernack
Jon Amund Eriksen
Mona Moller
Marianne Klemp Gjertsen
Ingvil Saeterdal
Original Assignee
Gemvax As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemvax As filed Critical Gemvax As
Publication of HK1036997A1 publication Critical patent/HK1036997A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK01107827A 1998-05-08 2001-11-08 Peptides HK1036997A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO19982097A NO315238B1 (no) 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
PCT/NO1999/000143 WO1999058552A2 (fr) 1998-05-08 1999-05-03 Utilisation d'analogues d'acides gras non beta-oxydables pour traiter les etats lies au syndrome x

Publications (1)

Publication Number Publication Date
HK1036997A1 true HK1036997A1 (en) 2002-01-25

Family

ID=19902021

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01107827A HK1036997A1 (en) 1998-05-08 2001-11-08 Peptides

Country Status (13)

Country Link
US (4) US6759046B1 (fr)
EP (2) EP2374814B1 (fr)
JP (1) JP4591983B2 (fr)
CN (1) CN100355781C (fr)
AR (1) AR018346A1 (fr)
AU (1) AU755712B2 (fr)
CA (1) CA2327549C (fr)
ES (1) ES2463825T3 (fr)
HK (1) HK1036997A1 (fr)
HU (1) HUP0101432A3 (fr)
NO (1) NO315238B1 (fr)
PL (1) PL344341A1 (fr)
WO (1) WO1999058552A2 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
GB2361701A (en) * 2000-04-28 2001-10-31 Norsk Hydro As DNA polymerase delta mutants
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
CA2471735A1 (fr) * 2001-08-29 2003-03-13 Kyogo Itoh Desensibilisants
AU2003232485A1 (en) 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
EP1369126A1 (fr) * 2002-04-18 2003-12-10 MTM Laboratories AG Utilisation de peptides de régions de microsatellites codantes et mutantes de déphasage pour traiter le cancer
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2004058157A2 (fr) * 2002-12-16 2004-07-15 Globeimmune, Inc. Vaccins a base de levure pour immunotherapie
CN102558334B (zh) * 2004-09-07 2016-08-03 伯纳姆研究院 选择性锚定到心脏脉管系统上的肽和相关结合物和方法
US7501486B2 (en) 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP1994181A4 (fr) * 2006-02-27 2010-05-19 Univ Arizona Identification et utilisation de novopeptides pour le traitement du cancer
ES2657480T3 (es) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
KR20100015661A (ko) * 2007-03-19 2010-02-12 글로브이뮨 암의 표적 치료법의 돌연변이성 이탈의 표적 절제를 위한 조성물 및 방법
US20080293050A1 (en) * 2007-05-25 2008-11-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Gene analysis for determination of a treatment characteristic
CA2715611C (fr) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapie ciblant des agents pathogenes intracellulaires
ES2545885T3 (es) 2008-02-14 2015-09-16 Life Sciences Research Partners Vzw Eliminación de respuestas inmunitarias contra vectores virales
ES2650236T3 (es) 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw Linfocitos T CD4+ con propiedades citolíticas
CA2715517C (fr) 2008-02-14 2018-07-24 Life Sciences Research Partners Vzw Peptides immunogenes et leur utilisation pour la prevention ou le traitement du rejet d'une allogreffe
CA2724440C (fr) * 2008-02-14 2018-01-09 Life Sciences Research Partners Vzw Strategies de prevention et/ou de traitement de reponses immunitaires dirigees contre des facteurs allogenes solubles
AU2009214039B2 (en) * 2008-02-14 2013-09-19 Katholieke Universiteit Leuven Immunogenic control of tumours and tumour cells
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
CN105132395A (zh) 2009-03-09 2015-12-09 生物蛋白有限公司 Mirac蛋白
PT2643345T (pt) 2010-11-25 2021-04-14 Imnate Sarl Péptidos imunogénicos para utilizar na prevenção e/ou no tratamento de doenças infecciosas, doenças autoimunes, respostas imunitárias a alofatores, doenças alérgicas, tumores, rejeição de enxertos e respostas imunitárias contra vetores virais usados para a terapêutica de genes ou na vacinação genética
MX355759B (es) 2011-10-28 2018-04-27 Oncotherapy Science Inc Peptidos topk y vacunas que incluyen los mismos.
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2013150532A1 (fr) * 2012-04-04 2013-10-10 Yeda Research And Development Co. Ltd. Conjugués de lipopeptide comprenant un sphingolipide et des peptides dérivés de gp41 du vih
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
US9205140B2 (en) 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
HUE065689T2 (hu) 2014-11-26 2024-06-28 The United States Of America Anti-mutált KRAS T sejt receptorok
KR20180006945A (ko) 2015-05-13 2018-01-19 아게누스 인코포레이티드 암 치료 및 예방용 백신
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP2016028025A (ja) * 2015-07-29 2016-02-25 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
CA2995771A1 (fr) 2015-09-25 2017-03-30 Imcyse Sa Procedes et composes ameliores pour supprimer des reponses immunitaires a des agents therapeutiques
WO2017069627A1 (fr) * 2015-10-23 2017-04-27 Universiteit Twente Peptides de liaison à l'intégrine et leurs utilisations
CN108495649A (zh) 2016-01-08 2018-09-04 瓦西博迪公司 治疗性抗癌新表位疫苗
ES2944259T3 (es) * 2016-03-15 2023-06-20 Inst Nat Sante Rech Med Procedimiento para activar la respuesta antitumoral de linfocitos T CD8+ de un paciente afectado con un cáncer
KR20220132023A (ko) 2016-04-19 2022-09-29 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
GB201608052D0 (en) * 2016-05-09 2016-06-22 Univ Oslo Hf T-cell receptors which recognise frameshift mutants of TGF-beta RII
WO2018039302A1 (fr) * 2016-08-23 2018-03-01 The Cleveland Clinic Foundation Traitement du cancer à l'aide de peptides bloquant cx26
US11260101B2 (en) 2017-02-28 2022-03-01 Jinan University Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
EP3630130B1 (fr) * 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University Procédé de création de vaccins anticancéreux personnalisés
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法
EP3827262A1 (fr) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer du sein
WO2020022903A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins à base de arid1a, cdkn2a, kmt2b, kmt2d, tp53 et pten contre le cancer
CA3106570A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer de l'uterus
WO2020022900A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer du rein
US12005104B2 (en) 2018-07-26 2024-06-11 Curevac Netherlands B.V. Cancer vaccines for colorectal cancer
LT3840767T (lt) 2019-05-29 2024-02-26 Hubro Therapeutics As Peptidai
EP4038222A4 (fr) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Procédés et compositions pour identifier des néo-antigènes destinés à être utilisés dans le traitement et la prévention du cancer
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
CN113061165A (zh) * 2020-01-02 2021-07-02 厦门大学 EB病毒BNLF2b基因编码多肽及其检测用途
WO2021142007A1 (fr) * 2020-01-09 2021-07-15 Arizona Board Of Regents On Behalf Of Arizona State University Anticorps et procédé de production d'anticorps
WO2021239980A2 (fr) 2020-05-28 2021-12-02 Hubro Therapeutics As Cocktail peptidique
WO2024052542A2 (fr) 2022-09-09 2024-03-14 Hubro Therapeutics As Cocktail de peptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9410922D0 (en) 1994-06-01 1994-07-20 Townsend Alain R M Vaccines
WO1996018409A1 (fr) 1994-12-14 1996-06-20 The Scripps Research Institute Activation in vivo de lymphocytes t cytotoxiques specifiques de tumeurs
US5866323A (en) * 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
US5958684A (en) 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
US5973018A (en) * 1995-10-04 1999-10-26 Owens-Corning Fiberglas Technology, Inc. Process for producing shaped phenolic foams
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU4907797A (en) 1996-10-10 1998-05-05 Wistar Institute Of Anatomy And Biology, The Methods and compositions for inducing a protective immune response to cancers
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides

Also Published As

Publication number Publication date
EP1078000B1 (fr) 2017-03-29
CA2327549A1 (fr) 1999-11-18
CN100355781C (zh) 2007-12-19
CA2327549C (fr) 2014-10-07
US6759046B1 (en) 2004-07-06
EP2374814B1 (fr) 2014-03-19
PL344341A1 (en) 2001-11-05
NO982097D0 (no) 1998-05-08
US8614177B2 (en) 2013-12-24
AU5451699A (en) 1999-11-29
CN1305495A (zh) 2001-07-25
ES2463825T3 (es) 2014-05-29
HUP0101432A2 (hu) 2001-08-28
JP2002519999A (ja) 2002-07-09
US20050074849A1 (en) 2005-04-07
JP4591983B2 (ja) 2010-12-01
AR018346A1 (es) 2001-11-14
NO315238B1 (no) 2003-08-04
WO1999058552A3 (fr) 2000-03-02
EP2374814A3 (fr) 2012-01-11
NO982097L (no) 1999-11-09
AU755712B2 (en) 2002-12-19
US20110105721A1 (en) 2011-05-05
US20070004632A1 (en) 2007-01-04
US7863244B2 (en) 2011-01-04
WO1999058552A2 (fr) 1999-11-18
HUP0101432A3 (en) 2004-01-28
EP2374814A2 (fr) 2011-10-12
EP1078000A2 (fr) 2001-02-28
US7192927B2 (en) 2007-03-20

Similar Documents

Publication Publication Date Title
HK1036997A1 (en) Peptides
GB9912852D0 (en) Peptides
HK1039158A1 (zh) Nlk1相互作用蛋白
GB9825854D0 (en) Peptide
GB9718110D0 (en) Peptides
GB0127673D0 (en) Polypeptide
GB9812675D0 (en) Peptides
GB9700154D0 (en) Peptides
EP1147130A4 (fr) Peptides d&#39;alpha-conotoxine
EP1159288A4 (fr) Peptides alpha-conotoxine
GB9904695D0 (en) Peptide
GB9828704D0 (en) Proteins
GB9816337D0 (en) Proteins
EP0996457A4 (fr) Peptides liberateurs de f.s.h.
GB9807890D0 (en) Peptides
IL144376A0 (en) Peptides
GB9908920D0 (en) Peptide
GB0224538D0 (en) Polypeptide
EP1151100A4 (fr) Peptides designes tau-conotoxines
GB9819038D0 (en) Protein
GB9809566D0 (en) Protein
GB9812607D0 (en) Protein
GB9818368D0 (en) Vitronectin-derived peptides
GB9827603D0 (en) Peptides
GB9800321D0 (en) Peptides

Legal Events

Date Code Title Description
PE Patent expired